EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Epitomee Medical Ltd (EPIT) fair value: what the stock is really worth

As of Oct 9, 2026: fair value of Epitomee Medical Ltd ILS 2.34, price ILS 3.59, upside -34.8%, quality 35 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · Il · ISIN IL0011825911

EM Thin data Oct 3, 2026

Epitomee Medical Ltd

EPIT · TA

Weak valuationQuality is weak on top of the rich price.

Low debt
Fair value 2.34 ILA · Overvalued (−34.8%)
Quality 35/100
Weak Growth
Negative free cash flow
Trails peers (2/8)
Narrow moat 12/100
Thin data
Watch Epitomee Medical Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

40.93 ILA 2.03 ILA Fair Value 2.34 ILA Dec 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

58‑month range 2.03 ILA – 40.93 ILA · fair‑value band 1.54 ILA – 2.92 ILA · the 3.59 ILA price screens above the 2.34 ILA fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow Epitomee Medical in your weekly email

Every Wednesday you see whether Epitomee Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Epitomee Medical Ltd develops and commercializes ingestible therapeutic devices in Israel. The company offers capsules for the treatment of overweight and obesity. It also focuses on developing biologic drug delivery solutions. Epitomee Medical Ltd was incorporated in 2005 and is based in Caesarea, Israel.

Stock analysis

Epitomee Medical Ltd (EPIT) currently trades at 3.59 ILA, while our model-based Fair Value estimate is 2.34 ILA, 34.8% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: 1.54 ILA (bear) to 2.92 ILA (bull), the price of 3.59 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Epitomee Medical Ltd reported revenue of $735K in FY2025 versus $0 in FY2021. Reported net income was −$29.7M in FY2025.

Key figures

Market cap 133M ILA · EPS (TTM) −1.01 ILA · Return on equity −37.9% · Return on assets (EBIT) −30.3% · Operating margin −815% · Revenue (TTM) $778K · Free cash flow −$30.5M · Net cash $25.8M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 63% below its 52-week high and 76% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −35%, EPIT screens richer than that median.

Fair Value models

Bear 1.54 ILA Fair Value 2.34 ILA Bull 2.92 ILA
Price 3.59 ILA · Upside -34.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 4.20 ILA 5.63 ILA 8.41 ILA 54
All 1 models by family
Asset-Based
NCAV (Graham) 4.20 ILA 5.63 ILA 8.41 ILA 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

Of which business quality 35 · Market factors (momentum, volatility) 24

Profitability 0
Margins and returns on capital today
Quality Growth 27
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 10
Distance to the 52-week high (market factor)
Net Issuance 78
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EPIT screens overvalued: fair value 35% below the price. Compare with Abbott Laboratories, →

Compare Epitomee Medical Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 329 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Bottom 25%
Fair Value upside −34.7% · Below median
Profitability
Return on assets −18.2% · Bottom 25%
Growth and dividend
Revenue growth 0.0% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.52× · Cheapest 25%
P/S (TTM) 55.64× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 8
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 17
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $275.43 $302.97 +10% vs EPIT
Boston Scientific Corporation BSX $42.19 $46.41 +10% vs EPIT
DexCom, Inc DXCM $85.36 $93.90 +10% vs EPIT
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10% vs EPIT
STERIS plc STE $208.93 $229.82 +10% vs EPIT
GE HealthCare Technologies Inc GEHC $65.74 $70.37 +7% vs EPIT
Edwards Lifesciences Corporation EW $85.78 $81.94 −4% vs EPIT
Medtronic plc MDT $86.38 $65.61 −24% vs EPIT
Abbott Laboratories, ABT $100.10 $74.79 −25% vs EPIT
Koninklijke Philips N.V PHIA €21.87 €15.23 −30% vs EPIT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Epitomee Medical Ltd · Fair Value
2.34 ILA −35%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Epitomee Medical Ltd Fair Value". https://www.fairvalue-calculator.com/stock/EPIT

Frequently asked questions

Is Epitomee Medical Ltd (EPIT) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 2.34 ILA versus a price of 3.59 ILA, about −35% upside (overvalued).
What is the fair value of EPIT?
Our model-based fair value for Epitomee Medical Ltd is 2.34 ILA (as of Oct 3, 2026), built from audited fundamentals. The current price: 3.59 ILA.
What is the quality score of EPIT?
Epitomee Medical Ltd has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Epitomee Medical Ltd (EPIT)?
Our model-based price target is the fair value of 2.34 ILA (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 1.54 ILA, optimistic scenario 2.92 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Epitomee Medical Ltd stock forecast for 2026?
Our models put fair value at 2.34 ILA, about −35% upside versus a price of 3.59 ILA (overvalued). Cautious scenario 1.54 ILA, optimistic scenario 2.92 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Epitomee Medical Ltd (EPIT)?
Epitomee Medical Ltd reported trailing-twelve-month revenue of about $778K (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Epitomee Medical Ltd (EPIT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Epitomee Medical Ltd it is 2.34 ILA per share (as of Oct 3, 2026), against a price of 3.59 ILA. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Epitomee Medical Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, EPIT trades above its calculated fair value: price 3.59 ILA, fair value 2.34 ILA, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EPIT?
No. The price is what the market pays today (3.59 ILA); the fair value is what the company's own numbers justify (2.34 ILA). For Epitomee Medical Ltd the two are 1.25 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Epitomee Medical Ltd worth?
The market values Epitomee Medical Ltd at about 133M ILA (market capitalisation, as of Oct 3, 2026). Per share that is 3.59 ILA; our models calculate a fair value of 2.34 ILA per share.
What do the bullish and bearish scenarios say about EPIT?
Our models span a range for Epitomee Medical Ltd: cautious scenario 1.54 ILA, base 2.34 ILA, optimistic 2.92 ILA per share (as of Oct 3, 2026, price 3.59 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Epitomee Medical Ltd (EPIT)?
Balance-sheet figures for Epitomee Medical Ltd (as of Oct 3, 2026): return on equity −37.9%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is EPIT from its 52-week high?
Epitomee Medical Ltd trades at 3.59 ILA, about 63% below its 52-week high of 9.78 ILA and 76% above the low of 2.03 ILA (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of 2.34 ILA is for.
Which stocks are comparable to Epitomee Medical Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Epitomee Medical Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price 3.59 ILA, calculated fair value 2.34 ILA (−35%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EPIT calculated?
We run Epitomee Medical Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.34 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Epitomee Medical Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Epitomee Medical Ltd (EPIT)?
The closing price on Oct 9, 2026 was 3.59 ILA. Our model-based fair value is 2.34 ILA, about −35% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Epitomee Medical Ltd right now?
The price sits above even our optimistic bull case (2.92 ILA). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1.54 ILA to 2.92 ILA) leaves room in how you read the outcome.

Key figures of Epitomee Medical Ltd

How large is the market capitalisation of Epitomee Medical Ltd (EPIT)?
The market capitalisation of Epitomee Medical Ltd is 133M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Epitomee Medical Ltd (EPIT)?
Earnings per share at Epitomee Medical Ltd are −1.01 ILA. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Epitomee Medical Ltd (EPIT)?
The return on equity (ROE) of Epitomee Medical Ltd is −37.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Epitomee Medical Ltd (EPIT)?
On an EBIT basis the return on assets of Epitomee Medical Ltd is −30.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Epitomee Medical Ltd (EPIT)?
The operating margin of Epitomee Medical Ltd is −815% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Epitomee Medical Ltd (EPIT) generate?
The free cash flow of Epitomee Medical Ltd is −$30.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Epitomee Medical Ltd (EPIT) hold?
Epitomee Medical Ltd holds more cash than debt, $25.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Epitomee Medical Ltd in the live analysis

One click puts Epitomee Medical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.